Zhou Q - Search Results

1

Combination of STING agonist and CXCR3 antagonist disrupts immune tolerance to overcome anti-PD-L1 resistance in lung adenocarcinoma under oxidative stress.

Zhu L, Gao H, Huang S, Cao T, Zhai X, Hu J, Wang T, Dong J, Liu Z, Chen J, Liu J, Zhang Z, Zhou Q. Zhu L, et al. Among authors: zhou q. Gene. 2023 Jan 30;851:146962. doi: 10.1016/j.gene.2022.146962. Epub 2022 Oct 19. Gene. 2023. PMID: 36272651

2

A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma.

Zhou Q, Sun X, Zeng L, Liu J, Zhang Z. Zhou Q, et al. Nanomedicine. 2009 Dec;5(4):419-23. doi: 10.1016/j.nano.2009.01.009. Epub 2009 Feb 13. Nanomedicine. 2009. PMID: 19523421 Clinical Trial.

3

The shadows hang over immunotherapy-neutrophil extracellular traps in cancer.

Pu D, Yin L, Zhai X, Wang R, Huang L, Wu Q, Zhu L, Zhou Y, Zhou Q, Li L. Pu D, et al. Among authors: zhou y, zhou q. Sci China Life Sci. 2023 May;66(5):1196-1199. doi: 10.1007/s11427-022-2243-4. Epub 2022 Dec 23. Sci China Life Sci. 2023. PMID: 36580164 No abstract available.

4

Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors.

Yu X, Zhu L, Wang T, Li L, Liu J, Che G, Zhou Q. Yu X, et al. Among authors: zhou q. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188910. doi: 10.1016/j.bbcan.2023.188910. Epub 2023 May 11. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37172653 Review.

5

Gas6/AXL pathway: immunological landscape and therapeutic potential.

Zhai X, Pu D, Wang R, Zhang J, Lin Y, Wang Y, Zhai N, Peng X, Zhou Q, Li L. Zhai X, et al. Among authors: zhou q. Front Oncol. 2023 May 10;13:1121130. doi: 10.3389/fonc.2023.1121130. eCollection 2023. Front Oncol. 2023. PMID: 37265798 Free PMC article. Review.

6

Immune cell membrane-based biomimetic nanomedicine for treating cancer metastasis.

Zhu L, Yu X, Cao T, Deng H, Tang X, Lin Q, Zhou Q. Zhu L, et al. Among authors: zhou q. Acta Pharm Sin B. 2023 Jun;13(6):2464-2482. doi: 10.1016/j.apsb.2023.03.004. Epub 2023 Mar 8. Acta Pharm Sin B. 2023. PMID: 37425034 Free PMC article. Review.

7

Personalized nanovaccines for treating solid cancer metastases.

Feng T, Hu J, Wen J, Qian Z, Che G, Zhou Q, Zhu L. Feng T, et al. Among authors: zhou q. J Hematol Oncol. 2024 Nov 28;17(1):115. doi: 10.1186/s13045-024-01628-4. J Hematol Oncol. 2024. PMID: 39609851 Free PMC article. Review.

8

A fusion-protein approach enabling mammalian cell production of tumor targeting protein domains for therapeutic development.

Hu J, Chen X, Zhang X, Yuan X, Yang M, Dai H, Yang W, Zhou Q, Wen W, Wang Q, Qin W, Zhao A. Hu J, et al. Among authors: zhou q. Protein Sci. 2018 May;27(5):933-944. doi: 10.1002/pro.3399. Epub 2018 Apr 14. Protein Sci. 2018. PMID: 29500915 Free PMC article.

9

[Influence of different mixing pads on physical and mechanical properties of glass ionomer cement].

Hu JY, Li L, Zhou QM, Ding RY, Shang R, Bai W. Hu JY, et al. Among authors: zhou qm. Beijing Da Xue Xue Bao Yi Xue Ban. 2019 Oct 18;51(5):964-967. doi: 10.19723/j.issn.1671-167X.2019.05.029. Beijing Da Xue Xue Bao Yi Xue Ban. 2019. PMID: 31624407 Free PMC article. Chinese.

10

The FoxO4/DKK3 axis represses IFN-γ expression by Th1 cells and limits antimicrobial immunity.

Chen X, Hu J, Wang Y, Lee Y, Zhao X, Lu H, Zhu G, Wang H, Jiang Y, Liu F, Chen Y, Kim BS, Zhou Q, Liu X, Wang X, Chang SH, Dong C. Chen X, et al. Among authors: zhou q. J Clin Invest. 2022 Sep 15;132(18):e147566. doi: 10.1172/JCI147566. J Clin Invest. 2022. PMID: 36106640 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22,475 results

Search Page

Filters